HitGen Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Li Jin

İcra Kurulu Başkanı

CN¥3.3m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.7yrs
CEO sahipliği	20.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

Oct 08

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

Jul 03

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Jun 06

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Mar 07

CEO

Li Jin (61 yo)

5.7yrs

Görev süresi

CN¥3,340,800

Tazminat

Mr. Li Jin serves as Chairman of the Board and General Manager at HitGen Inc.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Li Jin	Chairman & GM	5.7yrs	CN¥3.34m	20.5% CN¥ 1.1b
Lin Wang	Director	5.7yrs	Veri yok	Veri yok
Yunpei Guo	Independent Director	2.5yrs	CN¥120.00k	Veri yok
Jianguo Li	Director	5.7yrs	Veri yok	Veri yok
Jianming Wang	Director	1.5yrs	Veri yok	Veri yok
Dan Liu	Supervisor	2.5yrs	Veri yok	Veri yok
Haizong Yu	Independent Director	5.7yrs	CN¥120.00k	Veri yok
Li Suibo	Director	2.5yrs	CN¥1.03m	Veri yok

4.1yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688222 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

HitGen Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

HitGen Inc., Annual General Meeting, May 22, 2024

Recent updates

Price target increased by 43% to CN¥16.90

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023)

Now 23% overvalued after recent price rise

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

New minor risk - Share price stability

HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024

Now 20% overvalued

Now 25% overvalued

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

HitGen Inc., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)

HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released

New minor risk - Share price stability

Consensus EPS estimates fall by 41%

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)

HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023

HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research

Price target increased by 22% to CN¥23.00

First quarter 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.02 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Third quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.06 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥28.50

Full year 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.02 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.02 in 1Q 2020)

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.33 in FY 2019)

Revenue behind estimates

HitGen and UPPTHERA Entera Into Drug Discovery Research Collaboration

New 90-day high: CN¥40.13

New 90-day low: CN¥29.19

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of Novel Class of Drugs

Cedilla Therapeutics, Inc. and HitGen Inc. Announces Research Collaboration Focused on Dna-Encoded Library Based Drug Discovery

HitGen Licenses its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

New 90-day low: CN¥31.33

HitGen Inc. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥36.33

HitGen Inc. (SHSE:688222) agreed to acquire Vernalis (R&D) Limited from Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) for $25 million.

New 90-day low: CN¥37.61

New 90-day low - CN¥38.20

First half earnings released

New 90-day low - CN¥40.30

HitGen Inc. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş